SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending as the community debates its outlook ahead of earnings, with the stock drawing heavy interest from traders tracking its Pro segment performance and macro correlations to interest rates. Investors are actively weighing the impact of cooling consumer demand against potential upside from technical oversold signals and expected stability in dividend-paying assets.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings is trending as investors react to a strong quarterly earnings report that featured a revenue beat and raised guidance, fueling community optimism around its AI-driven growth. Despite the positive results, active discussion reflects frustration with ongoing share price volatility and short-term selling pressure, while long-term supporters remain focused on the company's expanding enterprise partnerships and AI-powered platform adoption.

Energy Vault Holdings, Inc. engages in the provision of energy storage solutions. The company was founded in September 2020 and is headquartered in Westlake Village, CA.

Energy Vault Holdings Inc

Energy Vault is currently trending as investors focus on recent strategic partnership announcements, including a major development agreement in South Africa and expansion into AI-dedicated infrastructure. While the community is actively debating the company's long-term potential versus concerns regarding dilution and volatility, sentiment remains split between bullish technical setups and frustration over recent market performance.

Dominion Energy, Inc. engages in the production and distribution of energy. It operates through following business segments: Dominion Energy Virginia, Dominion Energy South Carolina, Contracted Energy, and Corporate and Other. The Corporate and Other segment focuses on corporate, service company, non-controlling interest in Dominion privatization, and non-regulated retail energy marketing operations. The company was founded by William W. Berry in 1983 and is headquartered in Richmond, VA.

Dominion Energy Inc

Dominion Energy is trending following a significant merger agreement with NextEra Energy, creating a global utility powerhouse designed to meet surging power demand from AI data centers. The community is actively debating the deal's regulatory feasibility, the potential impact on customer electricity rates, and whether the all-stock transaction represents a bargain or an overextension.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is experiencing significant volatility and high trading volume as investors debate its valuation relative to larger semiconductor testing peers. The community is sharply divided, with some highlighting recent contract wins and capacity expansion as signs of a long-term rerating, while others caution against the stock's parabolic move and potential for a sharp reversal.

Amer Sports, Inc. engages in manufacturing, marketing, and selling sports equipment, apparel, and footwear. It operates through the following segments: Technical Apparel, Outdoor Performance, and Ball and Racquet Sports. The Technical Apparel segment refers to outdoor apparel, footwear, and accessories. It includes the Arc’teryx and Peak Performance brands. The Outdoor Performance segment focuses on outdoor apparel, footwear, accessories, and winter sports equipment. It includes the Salomon, Atomic, Armada, and ENVE brands. The Ball and Racquet Sports segment relates to sports equipment, apparel, and accessories. It includes the Wilson, Louisville Slugger, DeMarini, EvoShield, Atec, and Luxilon brands. The company was founded on January 03, 2020 and is headquartered in Helsinki, Finland.

Amer Sports Inc.

Amer Sports is trending as investors react to a strong quarterly earnings report that featured revenue growth and an upward revision to full-year guidance. The community is actively discussing the company's impressive profit margins, its portfolio of premium outdoor brands like Arc'teryx, and contrasting its performance with other consumer discretionary peers.

Agilysys, Inc. operates as a technology company. It offers innovative software for point-of-sale, payment gateway, reservation and table management, guest offers management, property management, inventory and procurement, analytics, document management, and mobile and wireless solutions and services to the hospitality industry. The firm also serves the gaming industry for both corporate and tribal, hotels resort and cruise, foodservice management, and the restaurant, university, and healthcare sectors. The company was founded in 1963 and is headquartered in Alpharetta, GA.

Agilysys, Inc

Agilysys is trending following a strong quarterly earnings report that featured a revenue beat and upward-revised forward guidance, fueling investor confidence in its subscription model and enterprise technology. The community is actively discussing the company's growth trajectory and momentum within the hospitality software sector, with many participants monitoring the stock for potential breakouts.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh its aggressive expansion into AI infrastructure and data centers against regulatory headwinds, specifically recent political proposals aimed at limiting institutional investment in residential real estate. While the stock faces near-term volatility from these policy risks, market participants remain focused on the company's massive dry powder and its pivotal role in financing the next wave of global AI compute capacity.

MakeMyTrip Ltd. engages in the provision of travel services. It offers air ticketing, hotels and packages, rail tickets, bus tickets, car hire, experiences and ancillary travel requirements such as foreign currency exchange services, visa processing, facilitating access to travel, and other insurance products. The company was founded by Deep Kalra and Rajesh Magow on April 28, 2000 and is headquartered in Gurgaon, India.

MakeMyTrip Ltd

MakeMyTrip is trending as investors monitor the company's strong category leadership and massive growth potential within India's expanding travel market, often drawing comparisons to other dominant global online travel agencies. While the stock has seen notable momentum and breakout patterns following solid earnings results, the community remains actively divided between those highlighting long-term structural tailwinds and those cautious of potential overvaluation or broader macroeconomic headwinds.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending as investors digest the company's recent expansion of its U.S. manufacturing infrastructure and its active pursuit of a harmonized global listing on the New York Stock Exchange. Community discourse remains focused on the drugmaker's robust oncology pipeline and its strategic positioning in competitive markets like obesity and hypertension.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Operating expenses fell in Q1 after Omeros sold its experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion.</li><li>Omeros is now awaiting a European Medicines Agency decision on the Yartemlea marketing authorization application.</li></ul>Omeros Corporation (OMER) shares rose more than 4% in after-hours trading on Wednesday after the company reported its first quarter of commercial revenue from the U.S. launch of YARTEMLEA for transplant-associated thrombotic microangiopathy (TA-TMA).Omeros posted first-quarter net product sales of $9.9 million, compared with zero in the year-ago period when the drug was not yet approved or launched, and above an estimated $4.11 million. Adjusted net loss narrowed to $0.24 per share, compared to a loss of $0.58 in the corresponding quarter of last year, and below a loss of $0.29 expected by Wall Street analysts.The company ended the quarter with $135.3 million in cash, cash equivalents, and short-term investments. Operating expenses fell sharply to $27.3 million from $35.0 million a year earlier, driven mainly by lower research and development spending after the earlier sale of the firm’s experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion.“The launch of YARTEMLEA has changed the trajectory of Omeros, both operationally and financially. We are seeing strong early adoption across transplant centers, expanding formulary access, favorable reimbursement support, and growing physician experience with the first and only approved treatment for TA-TMA,” CEO Gregory A. Demopulos said. Omeros launched Yartemlea in the U.S. in January for TA-TMA, or a severe, often fatal complication of bone marrow transplantation.Omeros also noted several upcoming catalysts, including a European Medicines Agency decision on the YARTEMLEA marketing authorization application expected in mid-2026. The company continues to advance its broader pipeline, including OMS527 for cocaine use disorder, and T-CAT programs targeting multidrug-resistant pathogens.<h2 class="st-heading-2">How Did OMER Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user opined that the after-hours price action does not justify the company’s “great” earnings call.<stembedurl>https://www.stocktwits.com/jmmoore4/message/653300780</stembedurl>Another user said that they see the stock climbing to $20 as the EMA decision nears and further to $100 in time.<stembedurl>https://www.stocktwits.com/MayorofMNKD/message/653296248</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has more than tripled in value over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/envx-stock-tumbles-after-hours-on-smartphone-battery-qualification-timeline-concerns/cZXLUN5ReKA">ENVX Tumbles After Hours On Smartphone Battery Qualification Timeline Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock Gains Ground As Commercial Rollout Of Yartemlea Exceeds Expectations  

Yartemlea net sales in Q1 came in at $9.9 million, higher than the $4.1 million expected by Wall Street. 

Equity

Yartemlea net sales in Q1 came in at $9.9 million, higher than the $4.1 million expected by Wall Street. 


Omeros Corporation Reports First Quarter 2026 Financial Results

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent...

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss...

Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and Brainsway

Medical Products stocks face tariff and cost pressures, but Phibro Animal Health and peers leverage innovation, AI and demand trends to drive growth.

Omeros (NASDAQ:OMER) Trading 6.3% Higher - Should You Buy?

Omeros (NASDAQ:OMER) Stock Price Up 6.3% - Should You Buy...

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

The consensus price target hints at a 222.8% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

4 Medical Product Stocks to Buy From a Challenging Industry

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

Omeros (NASDAQ:OMER) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen lowered Omeros from a "buy" rating to a "hold" rating in a research note on Sunday...

D. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER)

D. Boral Capital reissued a "buy" rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday...

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OMER News

OMEROmeros Corp